TASTE MASKING OF PRIFINIUM BROMIDE IN ORODISPERSIBLE TABLETS
Keywords:
Prifinium Bromide, Orodispersible tablets, Taste masking of active ingredient, Mass extrusion method, Eudragit E100, NilAbstract
Objective: In previous work, Prifinium Bromide had been successfully formulated as oro-dispersible tablets. However, Prifinium Bromide, a quaternary ammonium compound, has a bitter taste; therefore, taste masking was necessary to produce acceptable oro-dispersible tablets and enhance patients' compliance.
Methods: In this work, several attempts had been made to mask the bitterness of this drug. β-cyclodextrin inclusion complexes, solid dispersions of the drug in ethyl cellulose and methyl cellulose as well as loading the drug on Eudragit E100 have all been used. The selected granules were used to prepare oro-dispersible tablets and were evaluated.
Results: Drug-Eudragit granules E3 prepared by mass extrusion method gave less than 10% of drug in simulated saliva fluid and almost complete release in simulated gastric fluid after 2 minutes. Therefore, it was used to prepare oro-dispersible tablets formulas. In vitro disintegration time of formula T2 was 45.5 ± 7.7 seconds showed a complete drug release of Prifinium Bromide in phosphate buffer (pH 6.8) and (94%) in SGF (pH 2.1).
Conclusion: Loading of Prifinium Bromide on Eudragit E100 using mass extrusion method was the best method to overcome the disagreeable taste of the drug. They gave the least amount of drug released in simulated saliva fluid and passed the quality control tests of tablets after formulation as oro-dispersible tablets. They also gave good taste when tested in vivo.
Downloads
References
Ashish P, Mishra P, Main P. A review on-recent advancement in the development of rapid disintegrating tablet. Int J of Life Sci and Pharm Res 2011:1(1):7-16.
Strickley R, Iwata Q. Pediatric drugs-a review of commercially available oral formulations. J of pharm Sci 2008:97(5):1731-74.
Martindale, Sweetman, S C. Martindale:the complete drug reference. (Sean C. Sweetman, Ed.) London:Pharmaceutical Press;2009 (36th ed.):54, 1764, 1965.
Badgujar B P, Mundada A S. The technologies used for developing orally disintegrating tablets:a review. J Acta pharm 2011:61(2):117-39.
Swarbrick J. Encyclopedeia of Pharmaceutical technology. 3rd ed. Informa Healthcare;2006:1105-10, 1242, 68-1269, 3195-97.
Ramesh Kannuri T, Challa H C. Taste masking and evaluation methods for orodispersible tablets. J Int J of Pharmacy and Industrial Res 2011;1(3):200-10.
Dionysios Dennis Douroumis, Andreas Gryczke, S S. Development and evaluation of cetirizine HCl taste-masked oral disintegrating tablets. J AAPS Pharm Sci Tech 2011;12(1):141-51.
Sheth S K, Patel S J, Shukla J B. Formulation and evaluation of taste masked oral disintegrating tablet of lornoxicam. Int J of Pharm and Bio Sci 2010;1(2):1–9.
Swati C J, Vaibhav U G, Bhanudas S K A, Chabukswar R. Formulation and in vitro evaluation of taste-masked oro-dispersible dosage form of diltiazem hydrochloride. Brazilian J of Pharm Sci 2011:47(4):907-16.
Bhasin R K, Bhasin N, Kumar P. Advances in Formulation of Orally Disintegrating Dosage Forms:A review. Indo Global J of Pharm Sci 2011:1(4):328-53.
Momin M, Rathod S S K. Taste masking techniques for bitter drugs-an overview. Int J of Pharmacy and Technology 2012:4(2):2100-18.
Williams III R O, Taft D R, McConville J T. Advanced drug formulation design to optimize therapeutic outcomes. J Informa Healthcare 2007;219(172):226-27, 452-4.
Deepak S, Dinesh K, Mankaran S, Gurmeet S, Singh R M. Review article taste masking technologies :A novel approach for the improvement of organoleptic property of pharmaceutical active substance. Int Res J of Pharmacy 2012:3(4):108-16.
Al-Ghabban F. M., Al-Ani I. H., Hassan S. F., Salan N, Formulation and Evaluation of Prifinium Bromide and Prifinium Bromide –Diclofenac Sodium combination as Orodispersible tablets. Int J of Pharmacy and Pharm Sci 2013;5(suppl 2):652-9.
Narayana Raju P, Prakash K, Lakshmi Narasu M. Compatibility Study of Lamivudine with Various Cellulose Polymers. E J of Chemistry 2009:6(S1):17-20.
Freitas M R De, Rolim L A, Soares M F, Rolim-Neto P J, Albuquerque M M De, & Soares-Sobrinho J L. Inclusion complex of methyl-β-cyclodextrin and olanzapine as potential drug delivery system for schizophrenia. J Carbohydrate Polymers 2012:89(4):1095-100.
Gupte V V, Habib W, Holt K E, Khankari R K, & Hontz J. U.S. Patent Application 2002;(10):158,715.
Kawano Y, Ito A, Sasatsu M, Machida Y. Preparation of orally disintegrating tablets with taste-masking function:masking effect in granules prepared with correctives using the dry granulation method and evaluation of tablets prepared using the taste-masked granules. J of the Pharm Society of Japan 2010:130(1):81-6.
Uekama K., Design and evaluation of cyclodextrin-based drug formulation. Chemical, Pharm Bulletin 2004:52(8):900-15.
Rockville, MD. United States Pharmacopoeia:USP;32(2009).p. 226, 263, 272, 313, 382.